2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 987

Pesticide Exposure and Risk of Rheumatoid Arthritis in Licensed Male Pesticide Applicators in the Agricultural Health Study
Abstract Number: 988

Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 989

A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study
Abstract Number: 990

Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband
Abstract Number: 991

Familial Aggregation of Rheumatoid Arthritis in Sarcoidosis: A Register-Based Case-Control Study in Sweden
Abstract Number: 992

The Impact of Inflammatory Arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis) on Maternal and Neonatal Outcomes: A Population-Level Analysis
Abstract Number: 993

Chronic Widespread Pain Associated with Premature Mortality in a UK National Prospective Study
Abstract Number: 994

Validation Studies of the American College of Rheumatology (ACR) 2010 Fibromyalgia Diagnostic Criteria and the 2011 Self-Report Modification for Survey and Clinical Research
Abstract Number: 995

Use of Opiate Diminished the Treatment Benefits of Motivational Interviewing for Fibromyalgia
Abstract Number: 996

Use of a Shared Medical Appointment for Patients with Fibromyalgia in a Rural, Academic Medical Center: A Process Improvement Initiative for the Development of a New Care Model
Abstract Number: 997

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria
Abstract Number: 998

Brain Responses to Other’s Pain in Fibromyalgia – a Magnetoencephalography (MEG) Study
Abstract Number: 999

Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Abstract Number: 1000

Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
Abstract Number: 1001

Cytomegalovirus Reactivation in Connective Tissue Disease By Immunosuppressive Therapy Predicts Severe Infection and High Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].